Evidence map›Paper›PMID 33139818›Full record

ArticleCancer gene therapy2021

Long non-coding RNA HAND2-AS1 delays cervical cancer progression via its regulation on the microRNA-21-5p/TIMP3/VEGFA axis.

Yan Gao, Ting Zou, Wentong Liang, Zhijun Zhang, Mingrong Qie

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. A review on the role of HAND2-AS1 in cancer.Clinical and experimental medicine · 2023
    Review
  7. HNRNPA2B1-mediated mJournal of translational medicine · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yan GaoDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, 610041, P.R. China.
Ting ZouDepartment of Gynecology, Guizhou Provincial People's Hospital, Guiyang, 550002, P.R. China.
Wentong LiangDepartment of Gynecology, Guizhou Provincial People's Hospital, Guiyang, 550002, P.R. China.
Zhijun ZhangDepartment of Gynecology, Guizhou Provincial People's Hospital, Guiyang, 550002, P.R. China.
Mingrong QieDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, 610041, P.R. China. xmrjzz@126.com.ORCID http://orcid.org/0000-0002-6903-0625
Guizhou Provincial People's Hospital · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is a common cause of cancer-related mortality in women. Mounting evidence suggests that long non-coding RNAs (lncRNAs) function vitally in many cancers. In this study, we discovered that the regulation of the heart and neural crest derivatives expressed 2-antisense RNA 1 (HAND2-AS1) in cervical cancer. RT-qPCR was conducted to detect the expression of HAND2-AS1 and microRNA-21-5p (miR-21-5p). The relationship of HAND2-AS1 and miR-21-5p was identified by dual-luciferase reporter gene assay. The roles of HAND2-AS1, miR-21-5p and tissue inhibitor of metalloproteinases-3 (TIMP3) in cervical cancer were accessed via gain- and loss-of-function approaches. The expression of related proteins in the vascular endothelial growth factor A (VEGFA) signaling pathway was detected through Western blot analysis. Finally, xenografts of cervical cancer in nude mice were established to assess the effect of HAND2-AS1 on tumorigenesis in vivo. HAND2-AS1 and TIMP3 were downregulated in cervical cancer, which were identified to be associated with a poor prognosis of patients with cervical cancer. Moreover, HAND2-AS1 was upregulated the expression of TIMP3 through competitively binding to miR-21-5p. Overexpressed HAND2-AS1 or downregulated miR-21-5p inhibited cell proliferation, migration, and invasion while promoting cell apoptosis, in association with increased expression of proteins in VEGFA signaling pathway. These changes were reversed by silencing of TIMP3. Overexpressed HAND2-AS1 reduced the tumor formation ability in nude mice. In summary, HAND2-AS1 may exert inhibitory effects on cervical cancer cell growth and cervical cancer development through its regulation on the miR-21-5p/TIMP3/VEGFA axis. This highlights that HAND2-AS1 may serve as a potential target for cervical cancer diagnosis and treatment.

Indexed as

AdultAgedAnimalsCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHeterograftsHumansMiceMicroRNAsMiddle AgedNeoplasm InvasivenessRNA, Long NoncodingTissue Inhibitor of Metalloproteinase-3long non-coding RNA HAND2-AS1, humanMicroRNAsMIRN21 microRNA, humanRNA, Long NoncodingTIMP3 protein, humanTissue Inhibitor of Metalloproteinase-3Vascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID33139818
OpenAlexW3096257247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.